Everything below concerns hGH fragment. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-09-26. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
The registration certificate for the vaccine stated that it could not be used widely in Russia until 1 January 2021, and before that, it may be provided to "a small number of citizens from vulnerable groups", such as medical staff and the elderly, according to a Ministry of Health spokesperson. The license under register number No. ЛП-006395 (LP-006395) was issued on 11 August by the Russian Ministry of Health. Although the announcement was made even before the vaccine candidate had been entered into Phase III trials, the practice of marketing authorization "on conditions" also exists in other countries. On 26 August, certificate No. ЛП-006423 (LP-006423) was issued for the lyophilized formulation "Gam-COVID-Vac-Lyo". On 12 June 2021, developers announced that they had developed and tested a nasal vaccine for children aged 8 to 12, with no side effects found, and that they expected to release it on 15 September 2021.
In the first case of a woman being sentenced to death in Singapore, dance hostess Mimi Wong Weng Siu was convicted of murdering Ayako Watanabe out of jealousy in 1970 and received the death sentence in the same trial as her ex-husband Sim Woh Kum, who assisted her in killing the Japanese victim, who was the wife of Wong's Japanese boyfriend. The couple were executed on 27 July 1973.
=== Classification === A clinical severity score has been developed to assess chronic venous ulcers. It is based on the CEAP (clinical, etiology, anatomy, and pathophysiology) classification system developed by an expert panel. A high score gives a poor prognosis.
== History == The All-China Federation of Supply and Marketing Cooperatives traces its origins to the former Central Cooperation Administration, founded by central government in November 1949. The first representative conference of all cooperative workers in China was held in July 1950, and the conference passed documents such as the "Law of the People's Republic of China on Cooperatives (Draft)" (中华人民共和国合作社法（草案）) and the "Articles of Association of the All China Federation of Cooperatives (Draft)" (中华全国合作社联合总社章程（草案）). The All-China Federation of Cooperatives (中华全国合作社联合总社) was established, which unified the leadership and management of supply and marketing, production, fisheries, handicrafts, consumption, and credit cooperatives throughout the whole country. The All-China Federation of Supply and Marketing Cooperatives became a member of the International Cooperative Alliance (ICA) on 14 August 1985.
Sources: en.wikipedia.org
Renovo Group plc was a biopharmaceutical company founded in 1998 and headquartered in Manchester, United Kingdom. It worked in the discovery and development of drugs to reduce scarring, improve wound healing and enhance tissue regeneration. Renovo does not currently have any marketed products. It aimed "to be first to market with a scar prevention pharmaceutical drug in the US and Europe" in approximately 2014. Following the failure of its last clinical candidate, Juvista, all 100 of Renovo's staff were laid off in 2011. Although the company stopped all pharmaceutical development, it continued as a financial provider. In August 2014, Renovo Group plc was renamed Inspired Capital plc.
=== Indirect TPMS === Indirect TPMS (iTPMS) systems do not use physical pressure sensors; they measure air pressures using software-based systems, which by evaluating and combining existing sensor signals such as wheel speeds, accelerometers, and driveline data to estimate and monitor the tire pressure without physical pressure sensors in the wheels. First-generation iTPMS systems are based on the principle that under-inflated tires have a slightly smaller diameter (and hence higher angular velocity) than a correctly inflated one. These differences are measurable through the wheel speed sensors of ABS/ESC systems. Second generation iTPMS can also detect simultaneous under-inflation in up to all four tires using spectrum analysis of individual wheels, which can be realized in software using advanced signal processing techniques. iTPMS systems are sometimes referred to by other names, such as Ford's ‘Deflation Detection System (DDS)’ or Honda's ‘Deflation Warning System (DWS)’. iTPMS cannot measure or display absolute pressure values; they are relative by nature and have to be reset by the driver once the tires are checked and all pressures adjusted correctly. The reset is normally done either by a physical button or in a menu of the on-board computer. iTPMS are, compared to dTPMS, more sensitive to the influences of different tires and external influences like road surfaces and driving speed or style.
=== Border controls and traffic restrictions === Switzerland temporarily reintroduced controls at the border with France from 10 to 19 June 2026. The Federal Council stated that although the summit would take place in France, Geneva, Lausanne and the wider Lake Geneva region were exposed to security risks connected with the event. In the canton of Geneva, only seven road border crossings with France remained open from 12 to 18 June 2026: Anières, Moillesulaz, Thônex-Vallard, Bardonnex, Perly, Meyrin and Ferney-Voltaire. Crossings through railway stations and Geneva Airport remained authorised, but other crossings, including for cyclists and pedestrians, were restricted. Geneva authorities also warned of disruption to public transport, road traffic, as well as temporary restrictions affecting some public spaces. A priority access sticker system, known as a macaron, was introduced for eligible essential workers and residents. Geneva authorities stated that access to Switzerland remained possible without one, subject to controls and available crossings. Additional traffic restrictions were introduced on the Geneva motorway network, including restrictions on the A1 motorway between Geneva Airport and the Bardonnex customs crossing during the summit period.
Sources: en.wikipedia.org
==== Technical, trades, and vocational schools ==== During the 2010s, the value higher education came under heightened skepticism due to rising costs and disappointing results. According to the Department of Education, people with technical or vocational training are slightly more likely to be employed than those with a bachelor's degree and significantly more likely to be employed in their fields of specialty. By the late 2010s, the United States was facing a shortage of skilled tradespeople, because a majority of high-school students were still aiming for colleges and universities. But things were changing as more and more members of Generation Z considered alternatives to higher education. Career counselors are in extremely high demand; they are not only called for not just appointments invited to career fairs and orientation sessions for new students. With growing numbers of high-school students opting for trade schools and vocational training programs, enrollments in higher education have been falling.
=== As food === The inner bark is considered edible as an emergency food, even when raw. It can be dried and ground into flour, as was done by Native Americans and early settlers. It can also be cut into strips and cooked like noodles. The sap can be drunk or used to make syrup and birch beer. Tea can be made from the red inner bark of black birches.
=== Activators === 1-Aminoanthracene and propofol - activate SIRT2 activity on some substrates but inhibit it on others Nicotinamide riboside - activates SIRT2, but non selective Metformin - activates SIRT2 but has several other mechanisms of action as well SRT1720 - primarily a SIRT1 activator, but also weakly activates SIRT2 Hexapeptide-12 (VGVAPG) - upregulates SIRT2 gene expression through an indirect pathway
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.